GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (NAS:NERV) » Definitions » Cyclically Adjusted Price-to-FCF

Minerva Neurosciences (Minerva Neurosciences) Cyclically Adjusted Price-to-FCF : (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Minerva Neurosciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Minerva Neurosciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Minerva Neurosciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Neurosciences Cyclically Adjusted Price-to-FCF Chart

Minerva Neurosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Minerva Neurosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Minerva Neurosciences's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Minerva Neurosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Neurosciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Cyclically Adjusted Price-to-FCF falls into.



Minerva Neurosciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Minerva Neurosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Minerva Neurosciences's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.79/129.4194*129.4194
=-0.790

Current CPI (Dec. 2023) = 129.4194.

Minerva Neurosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.543 99.695 -0.705
201406 -1.113 100.560 -1.432
201409 -12.240 100.428 -15.773
201412 -2.169 99.070 -2.833
201503 -2.023 99.621 -2.628
201506 -2.275 100.684 -2.924
201509 -1.853 100.392 -2.389
201512 -2.136 99.792 -2.770
201603 -1.779 100.470 -2.292
201606 -1.663 101.688 -2.117
201609 -1.070 101.861 -1.359
201612 -2.048 101.863 -2.602
201703 -1.367 102.862 -1.720
201706 -1.491 103.349 -1.867
201709 4.871 104.136 6.054
201712 -1.841 104.011 -2.291
201803 -2.257 105.290 -2.774
201806 -2.317 106.317 -2.820
201809 -2.060 106.507 -2.503
201812 -2.016 105.998 -2.461
201903 -1.971 107.251 -2.378
201906 -2.077 108.070 -2.487
201909 -1.952 108.329 -2.332
201912 -2.906 108.420 -3.469
202003 -1.879 108.902 -2.233
202006 -1.507 108.767 -1.793
202009 -1.884 109.815 -2.220
202012 -1.341 109.897 -1.579
202103 -0.977 111.754 -1.131
202106 -1.110 114.631 -1.253
202109 -1.616 115.734 -1.807
202112 -0.905 117.630 -0.996
202203 -1.088 121.301 -1.161
202206 -0.972 125.017 -1.006
202209 -1.785 125.227 -1.845
202212 -0.770 125.222 -0.796
202303 -0.022 127.348 -0.022
202306 -0.703 128.729 -0.707
202309 -0.635 129.860 -0.633
202312 -0.790 129.419 -0.790

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Minerva Neurosciences  (NAS:NERV) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Minerva Neurosciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Neurosciences (Minerva Neurosciences) Business Description

Traded in Other Exchanges
Address
1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Executives
Ag Boehringer 10 percent owner BINGER STRABE 173, INGELHEIM AM RHEIN 2M 55216
Boehringer Ingelheim International Gmbh 10 percent owner 200 PARK AVENUE, C/O KLAUS H JANDER ESQ ROGERS & WELLS LL, NEW YORK NY 10166
Remy Luthringer officer: EVP and Head of R&D C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Geoff Race officer: EVP and CFO C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Frederick W Ahlholm officer: Chief Accounting Officer C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Kupfer director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Joseph H. Reilly officer: Chief Business Officer C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Van Heek G Jan director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Richard E. Russell officer: President C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
William F Doyle director
Hans Peter Hasler director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Index Venture Associates Iii Ltd 10 percent owner 5TH FLOOR, 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE1 3FG
Index Venture Associates Iv Ltd 10 percent owner 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE4 9WG

Minerva Neurosciences (Minerva Neurosciences) Headlines

From GuruFocus